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a B S T r a c T
Herein, joint recommendations for diagnosis and treatment of vulvo-vaginal atrophy (VVa) in women in the peri- and 
post-menopausal phases from the Società italiana per la Menopausa (SiM) and the Società italiana della Terza età (Si-
GiTe) are presented. The recommendations are aimed at all healthcare personnel caring for women in the menopausal 
transition or postmenopausal phase, and are also intended to raise awareness of VVa. recent data clearly indicate VVa 
is a highly prevalent condition among postmenopausal women, and that the vast majority of women with VVa are not 
adequately treated. in reality, diagnosis of VVa is simple and largely clinical. Many types of treatments are available for 
VVa, ranging from preventive education measures to local non-hormonal therapies, local agents that modulate hormonal 
receptors and systemic as well as laser therapy and radiofrequency. regardless of the therapeutic approach adopted, 
greater communication between the physician and the woman with VVa should be actively encouraged. This is also in 
light of the difficulty of talking about the VVA and related disorders. Greater communication also encourages adequate 
therapy and thus minimizes the impact of VVa on the quality of life of the woman and her partner.
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The present recommendations are aimed at all healthcare personnel who care for women 
in the menopausal transition or postmenopausal 
phase. The recommendations are addressed to 
italian healthcare professionals, although many 
considerations can have more outreaching value. 
The present considerations are intended to raise 
awareness and provide guidance on diagnosis 
and therapy of vulvo-vaginal atrophy (VVa). 
The need for these recommendations arises from 
two major considerations:
1) a recent study in italy indicated that al-
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are burdened by methodological defects that pre-
vent obtaining a clear picture of its actual preva-
lence. in epidemiological studies performed 
by hospital outpatient services across italy, it 
emerged that in postmenopausal women preva-
lence of vaginal atrophy is 79-81%. Prevalence 
appears to be around 65% at one year after meno-
pause, reaching 85% at 5 years after menopause. 
The most frequent objective sign is elevated pH, 
followed by the detection of a drier, paler mucosa 
with reduced folds. roughly 64% women with 
vaginal atrophy also have vulvar atrophy. Vagi-
nal atrophy also occurs in 20% to 55% of young-
er women between the age of 40 and 55 years.
The most frequent symptom of VVa is the 
sensation of vaginal dryness. Pain at intercourse 
is the second most common symptom, although 
its prevalence is higher in younger women and 
abruptly reduced at 5-7 years after menopause. 
The symptom referred to as the most bothersome 
by women is vaginal dryness, which is also pres-
ent in a 3-10% of post-menopausal women and 
in 25% of peri-menopausal women in which a 
clear diagnosis of VVa has not been established.
Quality of life and VVA
VVa normally appears in the period in which 
hormonal variations related to peri- and post-
menopause cause imbalances in the central ner-
vous system, which manifest as neurovegeta-
tive disorders, changes in mood and reduction 
in sexual desire. Within the framework outlined 
above, the symptoms resulting from VVa have 
a profound influence on the woman’s quality of 
life. The feeling of dryness and pain during inter-
course inevitably leads to feelings of inadequacy 
and decreased feeling of femininity, as well as 
a reduced number of sexual intercourse, desire 
and sexual satisfaction. These effects cannot be 
understood in their entirety if one does not con-
sider the reflexes of the partner who perceives 
a rejection of sexual intimacy. Such a situation 
leads to misunderstandings that, when generated 
in the sexual sphere, are transferred to personal 
relationships with moments of conflict and mis-
interpretation. Ultimately, the couple’s relation-
ship is undermined, with heavy repercussions on 
the quality of life of the couple and family.
most all (98%) of women with VVa are not ad-
equately treated. This is attributable to a number 
of factors, including the lack of diagnosis, which 
is often linked to the lack of physician-patient 
communication, and to wide differences in treat-
ments and their length of use;
2) there are no clear indications in the litera-
ture on how a diagnosis of VVa should be made 
and how it should be managed, in terms of thera-
pies, doses and time of administration.
Signs and symptoms of VVA
VVa refers to a clinical picture of dystrophy of 
the external genitals and vagina that is related to 
the combination of several factors, most often 
aging, reduced sexual activity and reduced or ab-
sent hormonal stimulation. The clinical features 
present with objective signs that are observed by 
the physician during clinical evaluation as well 
as patient-reported symptoms. objective signs 
include reduction of the maturation index of 
the vaginal epithelium and a vaginal pH>5. The 
signs revealed by the physician comprise vagi-
nal dryness, pallor and thinning of the mucosa, 
reduction and disappearance of vaginal folds, re-
duced vaginal elasticity, appearance of petechiae 
and mucosa lesions due to minimal trauma. at 
the vulvar level, there is a progressive reduction 
of the large and small lips, reduction of the cli-
toris, alterations of the urethral meatus that can 
become lumpy and lead to the appearance of ure-
thral caruncles, narrowing of the vaginal introi-
tus, thinning and pallor of the vulvar mucosa and 
appearance of petechiae, excoriations and ulcer-
ations on the mucosa. These alterations are also 
associated with modifications of the microbio-
logical niche up to the disappearance of lactoba-
cilli and colonization of the vagina by other mi-
croorganisms, which although not always patho-
genic, are less likely to defend the vagina from 
pathogenic bacteria. The symptoms of VVa are 
the sensation of dryness, pain during intercourse, 
burning, itching and recurrent vaginal infections.
Epidemiology of VVA
Many studies have attempted to define the preva-
lence of VVa with different approaches, but all 
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Preventive educational measures
even in the presence of low hormonal levels, the 
epithelium of the vaginal mucosa responds to the 
mechanical stimulus of the sexual act by preserva-
tion of its trophism and lubrication. The promotion 
of sexual intercourse is thus a mechanism in itself 
for prevention of VVa. The use of endo-vaginal 
stimulators can increase vascularization and vagi-
nal tropism and can be seen as an option to propose 
to women. in case of painful intercourse, lubricants 
can be useful, such as a gel based on lidocaine to be 
used on the vulvar region and the vaginal introit. 
in the case of vaginal narrowing, vaginal dilators 
together with lubricants may be considered.
Local non-hormonal therapies
The use of substances that can reduce the sensa-
tion of vaginal dryness is also of benefit in wom-
en who do not have sexual activity, as the sensa-
tion of dryness, even when isolated, is perceived 
by the majority women as the most bothersome 
symptom. reduction in vaginal dryness can be 
achieved with vaginal lubricants and moisturiz-
ers. it is important to note that these remedies are 
not able to restore the physiology of the vagina 
or promote maturation of the vaginal epithelium.
Water based lubricants and moisturizers con-
tain excipients that give them the appropriate 
viscosity, osmolarity and pH. The osmolarity 
should be around 320 and 1200 mOsm/kg, as 
higher values are irritating to the mucosa and 
are cytotoxic. The pH should be in the range of 
3.8 and 4.5. among excipients, parabens may 
be present, which have weak estrogenic activity, 
as well as glycols and glycerol/glycerin which 
influence osmolarity. In order to maintain an 
appropriate osmolarity, the amount of glycols 
should be <8.3% and that of glycerol/glycerin 
<9.9%. The excessive presence of glycerol and 
glycols is toxic to lactobacilli and promotes both 
herpes simplex infection and bacterial vaginosis. 
Furthermore, glycerol/glycerin can be used as a 
nutrient source by Candida albicans.
Vaginal lubricants
Vaginal lubricants are products based on aque-
ous gels, mineral oils, vegetable oils, or silicone-
Patient-physician communication
The italian aGaTa study showed that a clear 
diagnosis of VVa is not made in about 60% of 
postmenopausal women. This is related to the 
lack of communication between a woman and 
her gynecologist. Women do not easily talk 
about VVa and related disorders for a number 
of reasons: 1) they do not consider the symptoms 
to be relevant, as they believe the condition is 
an inevitable part of aging; 2) they consider the 
symptoms as not entirely burdensome and thus 
do not warrant therapy; 3) are embarrassed in 
dealing with the topic with their physician; 4) 
they perceive that the physician has a low level 
of interest; 5) they believe that there are no ef-
fective therapies. on the other hand, most physi-
cians do not query about the symptoms of VVa 
and about half of those who do seem to give little 
weight to patient-reported symptoms. a pro-ac-
tive approach by the physician is needed in deal-
ing with problems related to VVa. in addition to 
careful evaluation of the genitals, the physician 
must investigate any symptoms reported, as well 
as any other potential problems that the couple 
may have, and outline the course of VVa along 
with possible therapies.
Diagnosis of VVA
a diagnosis of VVa is established based on three 
parameters:
• vaginal pH>5;
• the sensation of vaginal dryness as reported 
by the patient;
• the presence of at least one of the following 
objective signs seen by the physician: presence 
of dry mucosa, pallor of the mucosa, fragility of 
the mucosa, thinning of vaginal folds, or pres-
ence of petechiae.
Thus, diagnosis is simple and is clinically fea-
sible in any ambulatory setting. The symptom of 
vaginal dryness as reported by the patient, ex-
ceeds a diagnosis of VVa in 3-9% of postmeno-
pausal women and in 27% of women between 40 
and 55 years. However, even in the absence of a 
clear diagnosis of VVa, the presence of symp-
toms, such as vaginal dryness, is an indication to 
start a therapy.
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improvement can sometimes be considered un-
satisfactory.
locally, various types of estrogens can be used, 
such as estradiol or estriol. Several formulations 
are now available (e.g. creams, gels, vaginal tab-
lets, or vaginal ring). all therapies performed 
with vaginal creams, gels, rings, or tablets with 
estradiol or estriol are equally effective, and the 
choice of formulation depends on the woman’s 
personal choice. Vaginal tablets and gels are less 
messy than creams and are often more pleasing 
for the woman in the long term. The available 
clinical studies suggest daily administration for 
the first 3 weeks, followed by two administra-
tions per week for 3-6 or 12 months. This dosage 
is based on controlled clinical trials, but it can 
be modified based on personal needs. The ring 
is left in place for 3 months and can be used for 
long-term administration.
Systemic absorption of hormones is minimal 
with most hormonal formulations, but still oc-
curs and for this reason the indication is to ad-
minister the estrogen at the lowest effective dose. 
This is most easily achieved with the adminis-
tration of estriol in the form of a gel or vaginal 
tablets. of note, due to systemic absorption such 
formulations are contraindicated in women with 
previous hormone-sensitive tumors. regard-
ing safety, increases in the incidence of venous 
thromboembolism and breast and endometrium 
cancer have not been reported in women under-
going low-dose vaginal estrogen therapy.
The safety of local estrogen on the endome-
trium has been demonstrated in studies with 
duration <12 months. The absence of long-term 
safety data suggests that in women who continue 
therapy for a longer period of time, ultrasound 
examinations of endometrial thickness should 
be performed; while there are no specific recom-
mendations regarding timing, it is reasonable to 
hypothesize once every 12 months.
Promestriene
There are few controlled clinical studies on the 
use of promestriene (3 propyl-ether-17 beta-
methyl-ether of estradiol) for the treatment of 
VVA. All short-term studies to date (20−40 days) 
seem to indicate that promestriene is effective for 
VVa. Promestriene is an estrogen that is not me-
based products. Their application in the vagina 
provides short-lasting but rapid relief of vaginal 
dryness and pain during intercourse. lubricants 
are therefore an acceptable option for women 
who only have dyspareunia or vaginal dryness 
during sexual intercourse. To reduce local side 
effects, water-based lubricants are preferred over 
those containing silicone. The WHo suggests the 
use of lubricants in association with condoms for 
menopausal women, in order to reduce the trans-
mission of sexually transmitted diseases.
Vaginal moisturizers
Vaginal moisturizers adhere to the vaginal mu-
cosa, promoting rehydration and mimicking the 
effect of vaginal secretions. They are used regu-
larly with a frequency that can range from one 
application per day to one every three days, de-
pending on the severity of the condition. Being 
moisturizers, the preparations contain water and 
other substances such as hyaluronic acid or poly-
carbophil. Some 3-month studies indicate that 
both hyaluronic acid and polycarbophil-based 
compounds are effective in reducing the symp-
toms of VVa, although studies on the latter com-
pounds in oncology patients have documented 
only transient benefits.
Other agents
There is some evidence to suggest that gels con-
taining bovine colostrum, vitamin D (not present 
in italy), or oxytocin (not present in italy) may 
have some benefits on symptoms.
Local agents that modulate 
hormonal receptors
Estrogens
local therapy with estrogens is considered to be 
the most effective treatment for VVa. Systemic 
estrogenic therapies are not indicated when the 
only symptom is disorders related to VVa. Sys-
temic or local hormone therapies are associated 
with an improvement in symptoms in 75% to 
85% of women, while the rate of remission of 
symptoms is observed in only about around 50% 
of cases. This indicates that all therapies have 
some degree of failure and that the perceived 
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Phyto-estrogens
Plant-based products containing phytestrogens 
may weakly stimulate the vaginal epithelium. 
Phyto-estrogens contained in Humulus lupulum, 
soy, or Pereraria mirifica, generally genistein, 
genistin and daidzein, dispersed in a gel formu-
lation and administered daily, may be effective 
in improving the symptoms and signs of VVa. 
However, there is limited information from 
clinical studies on effectiveness, which have 
also been limited to a few weeks of treatment. 
Phyto-estrogens are absorbed into systemic cir-
culation, and their systemic safety has not been 
ascertained.
Systemic modulation 
of hormone receptors
Ospemifene
ospemifene is the only oral molecule that is in-
dicated for treatment of VVa. it is a selective 
estrogen receptor modulator (SerM) that ex-
erts its action at the genito-urinary level. clini-
cal studies have shown that the administration 
of ospemifene at 60 mg/day improves the signs 
of vaginal atrophy, as well as the symptoms of 
VVa and sexual desire. clinical studies have 
also shown that ospemifene improves both vul-
var atrophy and vulvar pain. Being a SerM, 
ospemifene does not stimulate breast tissue and 
can also be administered to women who have un-
dergone surgical intervention for breast cancer, 
following the end of adjuvant therapies. Post-
marketing observational studies with data up to 2 
years have excluded that the daily and long-term 
administration of this drug is associated with an 
increased risk of breast tumors, endometrial hy-
perplasia, gynecological pathologies of any kind, 
or an increased risk of thrombosis and cardiovas-
cular disease. clinical studies appear to indicate 
that the efficacy of ospemifene on the symptoms 
and signs of VVa is similar to that of locally ad-
ministered estrogen, although there are no com-
parative studies.
Systemic hormonal therapies
Systemic hormone therapies are not indicated 
for the treatment of VVa alone. However, when 
tabolized into estradiol and estrone, but which 
induces a marked increase in uterine volume in 
experimental animal studies. although some au-
thors have suggested that promestriene can be 
used in women with hormone-sensitive tumors, 
there are as yet no data on safety to support this 
affirmation.
DHEA
DHea can be administered as vaginal ovules 
(6.5 mg). Four randomized placebo-controlled 
studies have shown that, compared to placebo, 
12-weeks of treatment with DHEA led to im-
provement of both objective signs and symptoms 
of VVA. In comparative studies, the efficacy of 
DHea was similar to that of conjugated equine 
estrogens or estradiol. DHea is converted to 
estradiol and testosterone in the vaginal epithe-
lium. While this effect is local, pharmacokinetic 
data indicate that there is an increase in exposure 
to the estrogenic and androgenic metabolites of 
DHea, even if circulating levels of estrogens 
and androgens remain in the normal range for 
postmenopausal women. No increases in the in-
cidence of venous thromboembolism or breast 
and endometrium cancer have been reported in 
women treated with DHea ovules at a dose of 
6.5 mg/day. Safety data are available for up to 
12 months of use, and there are no data on ef-
ficacy and safety in the longer term. Although its 
potential use has been hypothesized in women 
with hormone-sensitive/tumors, the compound 
does not currently have this indication. There 
are no data on the efficacy and safety of galenic 
preparations.
Testosterone
There are no registered and approved prepara-
tions for treatment of VVa based on testosterone. 
The use of testosterone in vaginal creams has 
been evaluated in a few clinical studies, which 
are mostly observational and limited to a period 
of 3 months. The scarcity of clinical studies sug-
gests that it should not be the first choice of treat-
ment. The administration of testosterone may 
induce a small increase in circulating estradiol. 
There are no data on the efficacy and safety of 
galenic preparations in the literature.
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device can be monopolar, bipolar, or multipolar, 
which differ in how the current passes through 
tissues where heat is generated. at a tissue tem-
perature of 40-45 °c, collagen synthesis, vascu-
larization and mucosal thickness are all stimulat-
ed. The instrument is activated and moved man-
ually by the operator, without direct or indirect 
automatic control of the temperatures reached in 
tissues. There are only very few clinical studies 
with radiofrequency, and long-term controlled 
clinical trials assessing efficacy and safety in ad-
equate populations are lacking. It should be high-
lighted that method and its effects are dependent 
on the operator, and are difficult to standardize 
and reproduce.
Duration of treatment
VVa develops when the vaginal mucosa or its 
hormone receptors are no longer stimulated by 
sexual activity and hormones. long-term ther-
apy consists of the use of treatments that favor 
or substitute sexual activity and the possibility 
to obtain adequate hormonal stimulation. There 
are no long-term data on the efficacy and safety 
of currently-available treatments for VVa. in the 
absence of this information, it is advisable to al-
ternate among different types of therapy accord-
ing to the age and needs of the woman with the 
objective of providing constant treatment (Fig-
ure 1). in the absence of long-term clinical trials, 
prolonging therapy requires reassessment of the 
efficacy and safety of the treatment at established 
times, with the possibility to adapt the dose and 
switch therapies in order to satisfy the needs and 
desires of the female patient.1-42
they are used for treatment of the systemic 
symptoms of menopause or for prevention of 
post-menopausal osteoporosis, they do improve 
the signs and symptoms of VVa similar to that 
seen with local estrogen treatment, even if there 
are no comparative studies. Systemic hormone 
therapies include several types of estrogens as-
sociated with various types of progestins, admin-
istered orally or transcutaneously, tibolone and 
the combination of estrogen and bazedoxifene 
(TSEC). The benefits and risks associated with 
systemic hormone therapies should be carefully 
be evaluated on a case by case basis.
Other therapies
Laser therapy
laser therapy has been used to manage VVa. 
Two types of lasers have been employed for 
VVa: a microablative co2 laser and the non-
ablative erbium-Smooth® laser. application of a 
laser increases the temperature of tissue in a con-
trolled manner, thus activating vasodilation and 
remodeling of collagen. laser therapy has been 
standardized and consists of three administra-
tions every 30 days. The results between the two 
types of lasers regarding vaginal atrophy appear 
to be broadly similar.
The data published to date indicates that laser 
treatment improves all the symptoms and the ob-
jective signs of VVa, and improves both sexual-
ity and the quality of life of women, similar to 
local pharmacological treatments. The effects of 
laser therapy seem to be lost at about 12 months 
after the end of treatment, and it is still unclear 
how often laser treatments should be repeated in 
the long-term. Similarly, it is not clear if laser 
therapy is associated with any undesirable vagi-
nal effects in the long term. laser therapy can be 
considered among the range of therapeutic op-
tions based on the woman’s specific needs and 
preferences and is of particular interest to wom-
en in whom systemic or local hormone therapies 
are contraindicated.
Radiofrequency
Radiofrequency creates an electric field that gen-
erates heat by moving molecules in tissue. The 
Figure 1.—indications for therapy for vulvo-vaginal atrophy 
(VVa) at various life stages.
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